Recent breakthroughs from Xiamen Biopharmaceutical Port include the market approvals of Class 1 innovative drugs: Inpegsomatropin Injection (brand name: Yipeisheng®), Fosrolapitant Palonosetron for Injection (Ruitanning®), and the domestically developed 9-valent HPV vaccine (Cecolin®9). These innovations not only fill critical technological gaps in China but also showcase the global competitiveness of Chinese intelligent manufacturing. Innovation remains the lifeline of biopharmaceutical development. After years of cultivation, the innovation-driven Xiamen Biopharmaceutical Port is now entering a phase of concentrated achievement output. Currently, nearly 60 innovative and improved drugs are in clinical trial phases, demonstrating diversified breakthroughs. Xiamen will accelerate the integration of biopharmaceutical industry, innovation, capital, talent, and service chains to propel enterprise growth.
